Literature DB >> 29104675

Fasting Ghrelin Levels Are Decreased in Obese Subjects and Are Significantly Related With Insulin Resistance and Body Mass Index.

Dimitrios Papandreou1, Christos Karavolias2, Fotini Arvaniti3, Eleana Kafeza4, Fatima Sidawi1.   

Abstract

BACKGROUND: Ghrelin is a 28-amino acid peptide that predominantly produced by the stomach. Strong evidence indicates the effects of ghrelin in the regulation of metabolic functions and its potential role in the aetiology of obesity. AIM: The aim of this study was to investigate the relationship of ghrelin levels with obesity, insulin resistance and glucose in normal and obese subjects.
METHODS: Thirteen normal (n = 13) and seven (n = 7) obese weight subjects aged 20-22 participated in the study. Fasting plasma ghrelin, insulin and glucose levels were measured after overnight fasting. HOMA-IR was calculated to evaluate insulin resistance.
RESULTS: Ghrelin and insulin levels were found to be statistically significantly lower and higher in obese subjects (P < 0.001), respectively. Glucose levels were clinically higher in obese subjects but not statistically significant. Fasting plasma ghrelin was negatively correlated with BMI (r = -0.77, P < 0.001), fasting insulin levels (r = -0.55, P < 0.001) and HOMA-IR (r = -0.66, P < 0.001). There was no correlation between ghrelin and glucose. In multiple regression analysis, insulin levels (Beta:-2.66, 95%CI:-2.49, -2.78, P < 0.001) HOMA-IR (Beta:-2.41, 95%CI:-2.33, -2.55, P < 0.001) and BMI (Beta:-1.77, 95%CI:-1.66, -1.89, P < 0.001) were significant independent determinants of fasting ghrelin.
CONCLUSION: Obese subjects have low fasting ghrelin levels that they are significantly related to insulin resistance and body mass index. More prospective studies are needed to establish the role of ghrelin in the pathogenesis of human obesity.

Entities:  

Keywords:  Body mass Index; Ghrelin; Insulin resistance; glucose; obesity

Year:  2017        PMID: 29104675      PMCID: PMC5661704          DOI: 10.3889/oamjms.2017.182

Source DB:  PubMed          Journal:  Open Access Maced J Med Sci        ISSN: 1857-9655


Introduction

Ghrelin is a 28-amino acid that is produced in the stomach. Other organs such as liver heart and pancreas can also produce ghrelin but in lower levels [1]. Strong evidence indicates the effects of ghrelin in its potential role in the pathogenesis of obesity, insulin resistance (IR) and types 2 diabetes [2]. More recently, research on ghrelin has improved our understanding of the mechanisms involve food intake, fat accumulation, and the development of other metabolic disturbances [3]. The role of ghrelin in the regulation of glucose was initially hypothesized after an observation of a negative correlation of insulin and ghrelin [4]. One year later Schofl et al. [5] supported the involvement of ghrelin in the development of IR and typed two diabetes. Total ghrelin levels have also been found to be negatively correlated with IR in children and adolescents [6]. Food intake is the most important factor that influences ghrelin levels. Usually, total ghrelin levels are rising during the night and decrease after breakfast [7]. A long-term high fat diet has found to reduce plasma total ghrelin levels and stomach content [8]. Also, many studies have reported that ghrelin levels are negatively associated with body mass index (BMI) [9, 10]. We hypothesized that obese individuals would present with elevated fasting ghrelin levels and there is no relationship between ghrelin and insulin levels.

Methods

Twenty healthy subjects (13 with normal weight and seven obese) participated in the study aged 20-22 years old. A detailed medical history was taken by the clinic’s doctor. Subjects with a medical history of liver, renal, or heart or taking any medications and supplements were excluded from the study. The study received approval from the ethical committees of “Zayed University” and “Doctors Medical Center” while all subjects signed a consent form. Body weight and height were collected for all subjects using SECA 600 model while obesity was defined as BMI>30 kg/m2, according to the criteria of International Obesity Task Force [11]. Plasma ghrelin, glucose, insulin and C-reactive protein (CRP) levels were measured in the morning after fasting overnight. Blood samples were drawn by a certified nurse by venipuncture into 10-ml empty evacuated placed on ice tubes. The tubes were immediately centrifuged at 2000 x g for 10 min. Plasma ghrelin levels were measure with the immunochemilunometric assay (IDS, SMBH, Germany) with an inter-assay coefficient of 6.2%. Plasma glucose levels were measured using a hexokinase enzymatic reference method (Cobas, Roche USA). Fasting insulin levels were measured using ECLIA method (Cobas 6000, Roche, USA) while CPR was measure with Immunoturbidimetry (Cobas 6000, Roche, USA). HOMA-IR was used to evaluate insulin resistance (fasting serum insulin (pmol/l) × fasting plasma glucose (mmol l-1)/22.5) [12].

Statistical Analysis

Fasting levels of ghrelin, glucose and insulin were compared by a t-test between normal and obese groups. Pearson’s correlations were calculated between anthropometric and biochemical variances and ghrelin levels. Moreover, the effect of several variables on ghrelin concentrations was considered with multiple linear regression analysis. In the regression model, we verified ghrelin as a dependent variable and included weight, BMI, glucose, Insulin, glucose and HOMA-IR as independent variables. Values with P < 0.05 were considered statistically significant.

Results

Fasting plasma levels were significantly lower in an obese subject compared to normal ones (Table 1, Figure 1). Also, BMI, plasma insulin and HOMA-IR were significantly higher in the obese group (Table 1).
Table 1

Baseline characteristics of Normal and Obese subjects

Normal (n = 13)OB (n = 7)p-value
Age, y21±0.821.±2.070.298
Height, cm159±8.2161±3.70.183
Weight, Kg53±8.779+110.001*
BMI, kg/m^220.6±331.3±2.10.001*
CRP1.2±1.12.0±1.00.065
Glucose, mmol/l5.1±6.55.5±6.70.072
Insulin, pmol/l8.2±2.714.5±2.30.041*
HOMA-IR1.85±0.53.54±0.80.004*
Ghrelin, pg/ml541±202440±1400.002*

Data is presented as mean ± SD;

P < 0.05 = Statistically significantly difference.

Figure 1

Ghrelin levels of obese subjects were statistically significant compare to normal ones (P < 0.005)

Baseline characteristics of Normal and Obese subjects Data is presented as mean ± SD; P < 0.05 = Statistically significantly difference. Ghrelin levels of obese subjects were statistically significant compare to normal ones (P < 0.005) Fasting plasma ghrelin was negatively correlated with BMI (r= -0.77, P<0.001), fasting insulin levels (r= -0.55, P < 0.001) and HOMA-IR (r = -0.66, P < 0.001). There was no correlation between ghrelin and glucose (Table 2).
Table 2

Pearson’s Correlation between Ghrelin and other variables

rp-value
Age0.510.332
Height-0.340.566
Weight-0.780.002*
BMI-0.770.001*
Glucose-0.510.455
Insulin-0.550.001*
HOMA-IR-0.660.001*

P<0.05: Statistically significant.

Pearson’s Correlation between Ghrelin and other variables P<0.05: Statistically significant. In multiple regression analysis, insulin levels (Beta: -2.66, 95% CI: -2.49, -2.78, P < 0.001) HOMA-IR (Beta: -2.41, 95% CI: -2.33, -2.55, P < 0.001) and BMI (Beta: -1.77, 95% CI: -1.66, -1.89, P < 0.001) were significant independent determinants of fasting ghrelin (Table 3).
Table 3

Multiple regression analysis of Ghrelin with anthropometric and biochemical variables

VariableBeta95% CIP
Weight-0.44-0.32, -0.550.505
BMI-1.77-1.66, -1.890.001*
Glucose-0.32-0.37, -0,490.668
Insulin-2.66-2.49, -2.780.001*
HOMA-IR-2.41-2.33, -2.550.001*

p < 0.05: Statistically significant.

Multiple regression analysis of Ghrelin with anthropometric and biochemical variables p < 0.05: Statistically significant.

Discussion

In our study contrary to our hypothesis, obese subjects have lower concentrations of ghrelin and higher insulin levels that the age-matched lean control subjects. This is an indication that ghrelin is downregulated in human obesity. This result may be because of elevated insulin levels since ghrelin levels were independently associated with insulin and HOMA-IR. These findings are in agreement with other research studies [13, 14]. Ghrelin was shown to inhibit insulin secretion from pancreatic islets in rodents [15]. Ghrelin secretion may be affected by adiposity through insulin and glucose metabolism [16]. Studies performed in humans demonstrated that i.v. Administration of insulin induces a fall in ghrelin levels [17]. Thus, reduced ghrelin levels in obesity may be the consequence of increased insulin levels in these subjects. In our study, ghrelin levels were negatively correlated with body weight and independently associated with BMI. Research evidence shows that plasma ghrelin levels are negatively correlated with body mass index and body fat percentage [18]. Also, reduced ghrelin secretion in obese patients was found to be an adaptive mechanism to a long-term positive energy balance [19]. The present study has some limitations that should be addressed. The small sample of the study has an important influence on the results. Also, we did not take in consideration any dietary habits, genetic information and socioeconomic factors that could also play an important role in obesity. Moreover, this was a one-time measure and may not represent the reality of the indices. Nevertheless, the results will provide some evidence of the relation of fasting ghrelin levels with insulin resistance and give some light on the pathogenesis of human obesity. In conclusion, Ghrelin is deregulated in obesity and associated with insulin and insulin resistance and thus may be considered a suitable target for the management of insulin resistance. More studies are needed to elucidate the effects of ghrelin in the pathogenesis of human obesity.
  18 in total

Review 1.  Physiological roles of ghrelin on obesity.

Authors:  Takahiro Sato; Takanori Ida; Yuki Nakamura; Yuki Shiimura; Kenji Kangawa; Masayasu Kojima
Journal:  Obes Res Clin Pract       Date:  2013-11-05       Impact factor: 2.288

2.  Ghrelin activates neuronal constitutive nitric oxide synthase in pancreatic islet cells while inhibiting insulin release and stimulating glucagon release.

Authors:  Saleem S Qader; Ingmar Lundquist; Mats Ekelund; Rolf Håkanson; Albert Salehi
Journal:  Regul Pept       Date:  2005-05-15

Review 3.  Ghrelin in Type 2 diabetes mellitus and metabolic syndrome.

Authors:  Olavi Ukkola
Journal:  Mol Cell Endocrinol       Date:  2011-03-23       Impact factor: 4.102

Review 4.  Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain.

Authors:  César Luiz Boguszewski; Gilberto Paz-Filho; Licio A Velloso
Journal:  Endokrynol Pol       Date:  2010 Mar-Apr       Impact factor: 1.582

5.  Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents.

Authors:  Ayako Ikezaki; Hiroshi Hosoda; Keiko Ito; Saika Iwama; Naoko Miura; Hisafumi Matsuoka; Chisato Kondo; Masayasu Kojima; Kenji Kangawa; Shigetaka Sugihara
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

6.  Circulating ghrelin levels are decreased in human obesity.

Authors:  M Tschöp; C Weyer; P A Tataranni; V Devanarayan; E Ravussin; M L Heiman
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

7.  Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans.

Authors:  Jonathan Q Purnell; David S Weigle; Patricia Breen; David E Cummings
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

8.  Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach.

Authors:  Sophia G Moesgaard; Bo Ahrén; Richard D Carr; Dorte X Gram; Christian L Brand; Frank Sundler
Journal:  Regul Pept       Date:  2004-08-15

9.  Circulating ghrelin levels in patients with polycystic ovary syndrome.

Authors:  Christof Schöfl; Rüdiger Horn; Thilo Schill; Hans W Schlösser; Manfred J Müller; Georg Brabant
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Establishing a standard definition for child overweight and obesity worldwide: international survey.

Authors:  T J Cole; M C Bellizzi; K M Flegal; W H Dietz
Journal:  BMJ       Date:  2000-05-06
View more
  2 in total

1.  Can a Higher Protein/Low Glycemic Index vs. a Conventional Diet Attenuate Changes in Appetite and Gut Hormones Following Weight Loss? A 3-Year PREVIEW Sub-study.

Authors:  Marion E C Buso; Radhika V Seimon; Sally McClintock; Roslyn Muirhead; Fiona S Atkinson; Shannon Brodie; Jarron Dodds; Jessica Zibellini; Arpita Das; Anthony L Wild-Taylor; Jessica Burk; Mikael Fogelholm; Anne Raben; Jennie C Brand-Miller; Amanda Sainsbury
Journal:  Front Nutr       Date:  2021-03-22

2.  Relationship Between Acyl and Desacyl Ghrelin Levels with Insulin Resistance and Body Fat Mass in Type 2 Diabetes Mellitus.

Authors:  Pu Zang; Cui-Hua Yang; Jun Liu; Hai-Yan Lei; Wei Wang; Qing-Yu Guo; Bin Lu; Jia-Qing Shao
Journal:  Diabetes Metab Syndr Obes       Date:  2022-09-07       Impact factor: 3.249

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.